A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder

Volume 325:1205-1209		October 24, 1991		Number 17

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder

DL Lamm, BA Blumenstein, ED Crawford, JE Montie, P Scardino, HB Grossman, TH Stanisic, JA Smith, J Sullivan, MF Sarosdy, and et al.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

BACKGROUND. In carcinoma of the bladder, both intravesical chemotherapy and immunotherapy can induce tumor regression and reduce the rate of recurrence, but the relative merits of these two therapies are unclear. We conducted a multi-institutional study to address this question. METHODS. Patients with rapidly recurrent (stage Ta and T1) or in situ transitional-cell carcinoma of the bladder were randomly assigned to receive either doxorubicin administered intravesically or bacille Calmette-Guerin (BCG) administered both intravesically and percutaneously. The 262 eligible patients were followed for a median of 65 months. Complete responses to treatment of carcinoma in situ were confirmed by biopsy and cytologic analysis of the urine. RESULTS. For patients with Ta and T1 tumors without carcinoma in situ, the estimated probability of being disease free at five years was 17 percent after doxorubicin, as compared with 37 percent after immunotherapy with BCG (P = 0.015). The median times to treatment failure (termination of treatment, due to persistence, recurrence, or progression of disease) were 10.4 and 22.5 months, respectively. For patients with carcinoma in situ the complete-response probability estimates (i.e., the estimated probability of documented disappearance of disease) were 34 percent for doxorubicin (23 of 67 patients) and 70 percent for BCG (45 of 64 patients) (P less than 0.001); the median times to treatment failure were 5.1 and 39 months, respectively. The probability of being disease-free at five years survival among the patients with carcinoma in situ was 18 percent after treatment with doxorubicin and 45 percent after BCG therapy. Patients treated with BCG had a higher incidence of toxic systemic effects and a larger number of local irritative symptoms than patients treated with doxorubicin, but few of these adverse reactions were severe. CONCLUSIONS. As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.

Source Information

West Virginia University Medical Center, Morgantown.

This article has been cited by other articles:

LEGG, J. S (2008). Bladder Cancer Imaging. radtech 79: 333-346 [Abstract] [Full Text]
Otterson, G. A., Villalona-Calero, M. A., Sharma, S., Kris, M. G., Imondi, A., Gerber, M., White, D. A., Ratain, M. J., Schiller, J. H., Sandler, A., Kraut, M., Mani, S., Murren, J. R. (2007). Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs. Clin. Cancer Res. 13: 1246-1252 [Abstract] [Full Text]
Parekh, D. J., Bochner, B. H., Dalbagni, G. (2006). Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. JCO 24: 5519-5527 [Abstract] [Full Text]
McKiernan, J. M., Masson, P., Murphy, A. M., Goetzl, M., Olsson, C. A., Petrylak, D. P., Desai, M., Benson, M. C. (2006). Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy. JCO 24: 3075-3080 [Abstract] [Full Text]
Dalbagni, G., Russo, P., Bochner, B., Ben-Porat, L., Sheinfeld, J., Sogani, P., Donat, M. S., Herr, H. W., Bajorin, D. (2006). Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guerin-Refractory Transitional Cell Carcinoma of the Bladder. JCO 24: 2729-2734 [Abstract] [Full Text]
Radl, R., Leithner, A., Kastner, N., Bodo, K., Nader, A., Windhager, R. (2005). Disappearance of a Cervical Spine Chordoma After Nonoperative Treatment. A Case Report. JBJS 87: 1822-1827 [Full Text]
Akaza, H., Koiso, K., Ozono, S., Kuroda, M., Kameyama, S., Okajima, E., Kotake, T., Kakizoe, T., Kawabe, K., the PMCJ-9 Study Group in Japan, (2003). A Clinical Study of PMCJ-9 (Bacillus Calmette-Guerin Connaught Strain) Treatment of Superficial Bladder Cancer and Carcinoma In Situ of the Bladder. Jpn J Clin Oncol 33: 382-390 [Abstract] [Full Text]
Laufer, M., Ramalingam, S., Schoenberg, M. P., Haisfield-Wolf, M. E., Zuhowski, E. G., Trueheart, I. N., Eisenberger, M. A., Nativ, O., Egorin, M. J. (2003). Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study. JCO 21: 697-703 [Abstract] [Full Text]
Davis, I. D., Jefford, M., Parente, P., Cebon, J. (2003). Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73: 3-29 [Abstract] [Full Text]
Crawford, E. D. (2002). Intravesical Therapy for Superficial Cancer: Need for More Options. JCO 20: 3185-3186 [Full Text]
Dalbagni, G., Russo, P., Sheinfeld, J., Mazumdar, M., Tong, W., Rabbani, F., Donat, M. S., Herr, H. W., Sogani, P., dePalma, D., Bajorin, D. (2002). Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guerin-Refractory Transitional-Cell Carcinoma of the Bladder. JCO 20: 3193-3198 [Abstract] [Full Text]
Meyer, J-P, Persad, R, Gillatt, D A (2002). Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad. Med. J. 78: 449-454 [Abstract] [Full Text]
Kuball, J., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D. C., Grace, M. J., Fritz, M. A., Storkel, S., Thuroff, J. W., Huber, C., Schuler, M. (2002). Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation. JCO 20: 957-965 [Abstract] [Full Text]
Hartmann, A., Schlake, G., Zaak, D., Hungerhuber, E., Hofstetter, A., Hofstaedter, F., Knuechel, R. (2002). Occurrence of Chromosome 9 and p53 Alterations in Multifocal Dysplasia and Carcinoma in Situ of Human Urinary Bladder. Cancer Res. 62: 809-818 [Abstract] [Full Text]
Hemstreet, G. P. III, Yin, S., Ma, Z., Bonner, R. B., Bi, W., Rao, J. Y., Zang, M., Zheng, Q., Bane, B., Asal, N., Li, G., Feng, P., Hurst, R. E., Wang, W. (2001). Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine. JNCI J Natl Cancer Inst 93: 427-436 [Abstract] [Full Text]
Brandau, S., Suttmann, H., Riemensberger, J., Seitzer, U., Arnold, J., Durek, C., Jocham, D., Flad, H.-D., Böhle, A. (2000). Perforin-mediated Lysis of Tumor Cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated Killer Cells. Clin. Cancer Res. 6: 3729-3738 [Abstract] [Full Text]
Mooren, F C, Lerch, M M, Ullerich, H, Bürger, H, Domschke, W (2000). Drug points: Systemic granulomatous disease after intravesical BCG instillation. BMJ 320: 219-219 [Full Text]
O'Donnell, M. A., Luo, Y., Chen, X., Szilvasi, A., Hunter, S. E., Clinton, S. K. (1999). Role of IL-12 in the Induction and Potentiation of IFN-{gamma} in Response to Bacillus Calmette-Guerin. J. Immunol. 163: 4246-4252 [Abstract] [Full Text]
Hall, R R (1994). Current Issues in Cancer: Superficial bladder cancer. BMJ 308: 910-913 [Full Text]

Comments and questions? Please contact us.